Home Companies Catalysts Deep Dives
Enbrel etanercept APPROVED
Drug Profile
ModalityFusion protein
RouteSC
Therapy AreaR&I
Launch1998-11-02
Peak Sales Est$8000M
Formulations[{"id":"enbrel-sc","doses":"50mg QW or 25mg BIW, SureClick autoinjector","route":"SC","setting":"PAT
Companies
AMGN (ORIGINATOR)100%
Mechanism: TNF inhibitor (fusion protein)
Expert: Dimeric fusion protein of p75 TNF receptor extracellular domain linked to Fc portion of IgG1. Competitively binds soluble TNF-alpha and lymphotoxin-alpha.
Everyday: A decoy receptor that soaks up TNF-alpha, a key inflammation driver, before it can trigger immune cells. Reduces joint inflammation, skin plaques, and other autoimmune damage.
Targets: ["TNF"]
Revenue History
PeriodRevenue ($M)
2024$3,316M
2025$2,226M
Q4 2024$1,015M
Q4 2025$532M
Programs (2)
IndicationStageKey StudyRegional Status
RAAPPROVEDPivotal RA trials[{"stage":"APPROVED","region":"US","approval_date":"1998-11-02"},{"stage":"APPRO
Plaque psoriasisAPPROVEDPivotal psoriasis trials[{"stage":"APPROVED","region":"US","approval_date":"2004-04-30"}]
Notes
DECLINING -33% YoY. Biosimilar erosion accelerating. Legacy franchise — still generating >$2B but on a clear downward trajectory.
Data from Supabase · Updated 2026-03-24